Having found changes in tumor uptake of 89Zr-radiolabeled antibodies after treatment with cetuximab or with INC280 and trametinib, we next investigated changes in MET, EGFR, and HER2 protein levels at the cellular level. Here, ERBB2 is linked to neoplasm.